Esreboxetine

From Self-sufficiency
Revision as of 15:28, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Esreboxetine
File:Esreboxetine.png
Systematic (IUPAC) name
(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 98819-76-2
ATC code none
Chemical data
Formula C19H23NO3
Molar mass 313.391 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1][2][3][4] It is the (+)-(S,S)-enantiomer of reboxetine and is even more selective in comparison.[1][5]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. 1.0 1.1 Matilda Bingham; Napier, Susan Jolliffe (2009). Transporters as Targets for Drugs (Topics in Medicinal Chemistry). Berlin: Springer. ISBN 3-540-87911-0. 
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. "Search of: esreboxetine - List Results - ClinicalTrials.gov". 
  4. "Musculoskeletal Report: Pfizer Stops Work on Esreboxetine for FM". 
  5. Fish, P. V.; MacKenny, M.; Bish, G.; Buxton, T.; Cave, R.; Drouard, D.; Hoople, D.; Jessiman, A.; Miller, D. (2009). "Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs". Tetrahedron Letters. 50: 389. doi:10.1016/j.tetlet.2008.11.025.  edit